{"id":"W3120580289","doi":"10.1093/ofid/ofaa439.1215","title":"1029. Long-Term Patient Adherence and Management of Treatment Interruptions With Long-Acting Injectable Cabotegravir + Rilpivirine for Maintenance Therapy in Phase IIb/III Studies","year":2020,"lang":"en","type":"article","venue":"Open Forum Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"ca_institutions":"GlaxoSmithKline (Canada)","funders":"","keywords":"Dosing; Medicine; Rilpivirine; Regimen; Clinical endpoint; Antiretroviral therapy; Internal medicine; Clinical trial; Human immunodeficiency virus (HIV); Viral load; Virology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00004808442,0.0003061016,0.0006043275,0.0000967563,0.0001571401,0.0000537596,0.00009174784,0.00002858313,0.00004787175],"category_scores_gemma":[0.00002050244,0.0002081742,0.00008517957,0.0002741793,0.0001003414,0.0002137901,0.0001456705,0.00005606392,0.000003959257],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002925279,"about_ca_system_score_gemma":0.0001095415,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001615083,"about_ca_topic_score_gemma":0.0007747426,"domain_scores_codex":[0.9986778,0.00003079848,0.0003758839,0.0004445747,0.0001353096,0.0003355654],"domain_scores_gemma":[0.9992536,0.00006629541,0.0001841254,0.0002087217,0.0001083272,0.0001789204],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.00436022,0.003382069,0.8053791,0.0004728604,0.002149111,0.0002493515,0.002926711,0.00003708362,0.00006335576,0.0002246131,0.0004279467,0.1803275],"study_design_scores_gemma":[0.2995927,0.1209723,0.4979615,0.0131856,0.005083668,0.0002646754,0.03623744,0.0009187616,0.01319925,0.0008378503,0.008534465,0.003211731],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9911999,0.001861858,0.0003913238,0.001049822,0.00005036202,0.004256899,0.00007536669,0.00005215763,0.001062283],"genre_scores_gemma":[0.9932666,0.003345358,0.0003961489,0.0002082525,0.00001440028,0.001608295,0.000108764,0.00003155315,0.001020639],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3074176,"threshold_uncertainty_score":0.8489099,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04923846734264716,"score_gpt":0.3537956273583668,"score_spread":0.3045571600157196,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}